Phio Share Price

Phio Share Price

NASDAQ: PHIO | Healthcare
$0.00
+0.00 (0.00%)
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Corporate Actions
  • About
  • Price history
  • FAQs

Phio Stock Performance

Open
N/A
Prev. Close
N/A
Circuit Range
N/A
Day Range
N/A
Year Range
$0.73 - $1.86
Volume
N/A
Average Traded
N/A

Phio Share Price Chart

Line chart of the Phio price trend over the selected period. The price rose overall, ranging from 0.73 to 0.74, ending at 0.74.
$0.00$0.00
L
Show Current Price
H

Phio Stock Fundamentals & Key Indicators

Market Cap
N/A
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-1.23
Revenue (TTM)
$0.00
Return On Equity (TTM)
-170.21%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-75.53%

Phio Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$2.37-$4.00-$4.14-$4.16
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-68.78%-3.50%-0.48%

Phio Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.00$0.00$0.00$0.00
Net Profit-$11.48-$10.83-$7.15-$8.70
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A5.66%33.98%-21.68%

Phio Balance Sheet

All figures in USD Million

Particulars2025202420232022
Non Current Assets0.010.00.040.37
Current Assets21.485.749.3212.45
Total Assets21.495.749.3612.81
Non Current Liabilities0.00.00.00.04
Current Liabilities1.341.021.631.94
Total Liabilities1.341.021.631.97
Shareholders' Equity20.154.727.7310.84

Phio Cash Flow

Annually

All figures in USD Million

Particulars2025202420232022
Operating-7.98-7.11-10.75-12.13
Investing-0.010.01-0.01-0.12
Financing23.644.07.41-0.03

Corporate Actions

Split
Ex-date: 05 Jul 2024

Split
Ex-date: 26 Jan 2023

Split
Ex-date: 15 Jan 2020

About Phio

Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.

Phio Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$0.89
$0.74
-13.29%
Oct 2026
$1.00
$0.86
-17.50%
Sep 2026
$1.06
$1.04
-7.14%
Aug 2026
$1.10
$1.12
+8.74%
Jul 2026
$1.02
$1.03
+0.49%
Jun 2026
$1.10
$1.02
-8.07%
May 2026
$1.20
$1.11
-8.98%
Apr 2026
$1.28
$1.23
-1.21%
Mar 2026
$1.07
$1.24
+9.25%
Feb 2026
$0.97
$1.14
+11.27%
Jan 2026
$1.05
$1.02
-1.92%
Dec 2025
$1.25
$1.04
-18.75%

Phio Share Price FAQs